rhenium-186-chelated nanoliposome
plus theraputics
['rhenium-186', 'respect-gbm', 'gbm']
doses of rhenium-186 nanoliposome above 100 gy improved overall survival in recurrent glioma, according to results from the phase 1 respect-gbm trial presented at 2022 esmo. #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.